Suppr超能文献

细胞程序性坏死不会在 SARS-CoV-2 的感染性小鼠模型中驱动疾病发病机制。

Necroptosis does not drive disease pathogenesis in a mouse infective model of SARS-CoV-2 in vivo.

机构信息

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, 3052, Australia.

Department of Medical Biology, University of Melbourne, Melbourne, VIC, 3050, Australia.

出版信息

Cell Death Dis. 2024 Jan 30;15(1):100. doi: 10.1038/s41419-024-06471-6.

Abstract

Necroptosis, a type of lytic cell death executed by the pseudokinase Mixed Lineage Kinase Domain-Like (MLKL) has been implicated in the detrimental inflammation caused by SARS-CoV-2 infection. We minimally and extensively passaged a single clinical SARS-CoV-2 isolate to create models of mild and severe disease in mice allowing us to dissect the role of necroptosis in SARS-CoV-2 disease pathogenesis. We infected wild-type and MLKL-deficient mice and found no significant differences in viral loads or lung pathology. In our model of severe COVID-19, MLKL-deficiency did not alter the host response, ameliorate weight loss, diminish systemic pro-inflammatory cytokines levels, or prevent lethality in aged animals. Our in vivo models indicate that necroptosis is dispensable in the pathogenesis of mild and severe COVID-19.

摘要

细胞程序性坏死,一种由混合谱系激酶结构域样(MLKL)伪激酶执行的溶细胞性细胞死亡方式,已被牵连到由 SARS-CoV-2 感染引起的有害炎症中。我们最小限度和最大限度地传代了单个临床 SARS-CoV-2 分离株,在小鼠中建立了轻度和重度疾病模型,使我们能够剖析程序性坏死在 SARS-CoV-2 疾病发病机制中的作用。我们感染了野生型和 MLKL 缺陷型小鼠,并未发现病毒载量或肺部病理有显著差异。在我们的严重 COVID-19 模型中,MLKL 缺陷并未改变宿主反应、减轻体重减轻、降低全身促炎细胞因子水平,或防止老年动物的致死性。我们的体内模型表明,程序性坏死在轻度和重度 COVID-19 的发病机制中是可有可无的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2636/10825138/0fbd76830bd3/41419_2024_6471_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验